Observational studyMedicine2026
Impact of histologic hepatic steatosis on virological response to nucleos(t)ide analogue therapy in patients with chronic hepatitis B.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B remains a major cause of cirrhosis and hepatocellular carcinoma worldwide. We investigated whether histologic hepatic steatosis affects hepatitis B virus deoxyribonucleic acid (HBV DNA) suppression in patients receiving antiviral therapy. This retrospective observational study included 307 adult patients with chronic hepatitis B who received tenofovir or entecavir therapy and underwent pretreatment liver biopsy. Demographic, laboratory, virological, radiological, and histopathological data were retrieved from the electronic medical record system. Laboratory parameters included complete blood count, liver function tests, alpha-fetoprotein, renal function tests, and lipid profile. Histopathological evaluation included fibrosis stage, histologic activity index, and hepatic steatosis percentage. Ultrasonographic findings included hepatic steatosis, liver echotexture, and contour. The primary outcome was HBV DNA suppression at 12 months. Long-term virological response was evaluated as time to first HBV DNA suppression during follow-up (maximum 60 months). A total of 307 patients receiving entecavir or tenofovir were included, of whom 258 (84.0%) achieved HBV DNA suppression at 12 months. Patients without suppression had higher baseline aspartate aminotransferase, histologic activity index, histologic steatosis, and baseline log10 HBV DNA levels (all P < .05). Histologic steatosis ≥5% was more frequent in patients without suppression (42.9% vs 23.6%, P = .005). In multivariable analysis, steatosis ≥5% (odds ratio 0.365, 95% confidence interval [CI] 0.179-0.746; P = .006) and higher baseline log10 HBV DNA (odds ratio 0.842, 95% CI 0.751-0.944; P = .003) were associated with a lower likelihood of 12-month suppression, with similar findings in the parsimonious sensitivity model. Kaplan-Meier analysis showed delayed suppression with steatosis (log-rank P = .016); however, this association was not significant in the conventional adjusted Cox model (hazard ratio 0.900, 95% CI 0.689-1.175; P = .438), and a significant time-dependent interaction indicated non-proportionality (P < .001). Histologic steatosis and higher baseline log10 HBV DNA were associated with a lower likelihood of 12-month HBV DNA suppression. However, an independent longitudinal association with time to suppression was not demonstrated. Residual confounding by unmeasured metabolic factors cannot be excluded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.